A Post-Authorisation Disease Registry Safety Study to Generate Data on the Long-Term Safety and Clinical Effectiveness of SCENESSE® (Afamelanotide 16mg) in Patients with Erythropoietic Protoporphyria (EPP). (SCENESSE® PASS-002) First published 01/04/2016 Last updated 13/02/2026 EU PAS number:EUPAS13004 Study Ongoing